Limited sampling strategy for estimating individual exposure of tacrolimus in pediatric kidney transplant patients

Therapeutic Drug Monitoring

Volumn 33, Issue 6, 2011, Pages 681-687

  Zhao, Wei ^a,b   Fakhoury, May ^a   Baudouin, Veronique ^a   Maisin, Anne ^a   Deschênes, Georges ^a   Jacqz Aigrain, Evelyne ^a,b  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b INSERM   (France)

Author keywords

Bayesian estimator; Kidney transplantation; Limited sampling strategy; Pediatrics; Population pharmacokinetic model; Regression analysis; Tacrolimus

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ACCURACY; ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BAYESIAN LEARNING; CHILD; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EXPOSURE; FEMALE; GRAFT RECIPIENT; HUMAN; KIDNEY TRANSPLANTATION; LIMITED SAMPLING STRATEGY; MALE; MATHEMATICAL PARAMETERS; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELIABILITY; SCHOOL CHILD; VALIDATION STUDY;

ADOLESCENT; BAYES THEOREM; CHILD; CHILD, PRESCHOOL; DRUG MONITORING; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MODELS, BIOLOGICAL; REGRESSION ANALYSIS; TACROLIMUS;

EID: 84856078734     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318235d067     Document Type: Article

References (27)

1. Scott LJ, McKeage K, Keam SJ, et al. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs. 2003;63:1247-1297. (Pubitemid 36750952)
2. Zhao W, Fakhoury M, Jacqz-Aigrain E. Developmental pharmacogenetics of immunosuppressants in pediatric organ transplantation. Ther Drug Monit. 2010;32:688-699.
3. Machida M, Takahara S, Ishibashi M, et al. Effect of temperature and hematocrit on plasma concentration of FK 506. Transplant Proc. 1991;23:2753-2754.
4. Christians U, Jacobsen W, Benet LZ, et al. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet. 2002;41:813-851.
5. Saeki T, Ueda K, Tanigawara Y, et al. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem. 1993;268:6077-6080. (Pubitemid 23099291)
6. Pawarode A, Shukla S, Minderman H, et al. Differential effects of the immunosuppressive agents cyclosporin A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins. Cancer Chemother Pharmacol. 2007;60:179-188. (Pubitemid 46742532)
7. Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet. 1995;29:404-430. (Pubitemid 26004179)
8. Wallemacq P, Armstrong VW, Brunet M, et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit. 2009;31:139-152.
9. Ting LS, Villeneuve E, Ensom MH. Beyond cyclosporine: a systematic review of limited sampling strategies for other immunosuppressants. Ther Drug Monit. 2006;28:419-430. (Pubitemid 44314932)
10. Claeys T, Van Dyck M, Van Damme-Lombaerts R. Pharmacokinetics of tacrolimus in stable paediatric renal transplant recipients. Pediatr Nephrol. 2010;25:335-342.
11. Filler G, Feber J, Lepage N, et al. Universal approach to pharmacokinetic monitoring of immunosuppressive agents in children. Pediatr Transplant. 2002;6:411-418. (Pubitemid 35265193)
12. Filler G, Feber J. The transplanted child: new immunosuppressive agents and the need for pharmacokinetic monitoring. Paediatr Child Health. 2002;7:525-532. (Pubitemid 35415607)
13. David OJ, Johnston A. Limited sampling strategies for estimating cyclosporin area under the concentration-time curve: review of current algorithms. Ther Drug Monit. 2001;23:100-114. (Pubitemid 32240136)
14. Zhao W, Elie V, Baudouin V, et al. Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome. Br J Clin Pharmacol. 2010;69:358-366.
15. van Gelder T, Le Meur Y, Shaw LM, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit. 2006;28:145-154. (Pubitemid 44314941)
16. del Mar Fernández De Gatta M, Santos-Buelga D, Domínguez-Gil A, et al. Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations. Clin Pharmacokinet. 2002;41:115-135.
17. Zhao W, Elie V, Roussey G, et al. Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. Clin Pharmacol Ther. 2009;86:609-618.
18. Kim JS, Aviles DH, Silverstein DM, et al. Effect of age, ethnicity, and glucocorticoid use on tacrolimus pharmacokinetics in pediatric renal transplant patients. Pediatr Transplant. 2005;9:162-169. (Pubitemid 40476842)
19. Shishido S, Asanuma H, Tajima E, et al. Pharmacokinetics of tacrolimus in pediatric renal transplant recipients. Transplant Proc. 2001;33:1066-1068. (Pubitemid 32237749)
20. Webb NJ, Stevenson PJ, Lewis MA, et al. Pharmacokinetics of tacrolimus in paediatric renal transplant recipients. Transplant Proc. 2002;34:1948-1950.
21. Montini G, Ujka F, Varagnolo C, et al. The pharmacokinetics and immunosuppressive response of tacrolimus in paediatric renal transplant recipients. Pediatr Nephrol. 2006;21:719-724.
22. Filler G, Grygas R, Mai I, et al. Pharmacokinetics of tacrolimus (FK 506) in children and adolescents with renal transplants. Nephrol Dial Transplant. 1997;12:1668-1671. (Pubitemid 27346294)
23. Figurski MJ, Nawrocki A, Pescovitz MD, et al. Development of a predictive limited sampling strategy for estimation of mycophenolic acid area under the concentration time curve in patients receiving concomitant sirolimus or cyclosporine. Ther Drug Monit. 2008;30:445-455.
24. Forbes N, Schachter AD, Yasin A, et al. Limited sampling strategies for sirolimus after pediatric renal transplantation. Pediatr Transplant. 2009;13:1020-1026.
25. Zhao W, Fakhoury M, Deschênes G, et al. Population pharmacokinetics and pharmacogenetics of mycophenolic acid following administration of mycophenolate mofetil in de novo pediatric renal-transplant patients. J Clin Pharmacol. 2010;50:1280-1291.
26. Miura M, Satoh S, Niioka T, et al. Early phase limited sampling strategy characterizing tacrolimus and mycophenolic acid pharmacokinetics adapted to the maintenance phase of renal transplant patients. Ther Drug Monit. 2009;31:467-474.
27. Scholten EM, Cremers SC, Schoemaker RC, et al. AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int. 2005;67:2440-2447. (Pubitemid 41623408)